comparemela.com
  1. Home
  2. Live Updates
  3. Matthewd Galsky - Breaking News

Matthewd Galsky News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

United statesSouth koreaPushkar muthaMariat bourlonTycel jovelle phillipsTony mokLin wangPeter robert galleCharlene mantiaMarc hoffmannEric christensonSuzanne trudelManali kirtikumar kamdarGuillermo garcia maneroMartin reckTina cascone

Blood-based DNA test spares bladder cancer patients from unnecessary treatments

Testing for tumor DNA in the blood can successfully identify advanced bladder cancer patients who will not relapse following surgery, new research shows.

France generalNew yorkUnited statesThomas powlesMatthew galskyMatthewd galskyJoost boormansIcahn school of medicine at mount sinaiRoche ltdEuropean association of urologyScientific congress officeBristol myers squibbEuropean association of urology congressTisch cancer instituteBarts cancer instituteEuropean association

Trials Reveal Improved, Targeted Bladder Cancer Treatments

Trials Reveal Improved, Targeted Bladder Cancer Treatments
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesFrance generalMatthew galskyThomas powlesJoost boormansMatthewd galskyRoche ltdBarts cancer instituteEuropean association of urology congressIcahn school of medicine at mount sinaiScientific congress officeBristol myers squibbTisch cancer instituteEuropean associationUrology congress

Gemcitabine, Cisplatin, Nivolumab Facilitate Bladder Sparing

Clinical complete response of 43% seen for those with muscle-invasive bladder cancer receiving neoadjuvant gemcitabine, cisplatin, plus nivolumab

New yorkUnited statesMatthewd galskyIcahn school of medicine at mount sinaiHealthday newsIcahn schoolMount sinaiNew york city

Gemcitabine, Cisplatin, and Nivolumab Facilitate Bladder Sparing in MIBC

Treatment with gemcitabine, cisplatin, and nivolumab facilitates bladder sparing in patients with muscle-invasive bladder cancer.

New yorkUnited statesMatthewd galskyIcahn school of medicine at mount sinaiHealthday newsIcahn schoolMount sinai

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.